Marker Therapeutics

About

Marker Therapeutics is a clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.

Minneapolis,Minnesota,United States
51 - 100
https://www.markertherapeutics.com/

Highlights

Details

Last Funding Type: Post-IPO Equity
Last Funding Money Raised: $25M
Industries: Biotechnology,Therapeutics
Founded date: Jan 1, 1992
Number Of Employee: 51 - 100
Operating Status: Active
Stock Symbol: nasdaq:MRKR
Legal Name: Marker Therapeutics, Inc.

Marker Therapeutics is a clinical stage immuno-oncology company focused on developing adoptive non-gene modified T cell therapies for the treatment of hematologic malignancies such as Acute Myeloid Leukemia, Lymphoma, and Multiple Myeloma. Marker’s MultiTAA technology selectively expands non-engineered T cells, enhancing them with the ability to kill tumor cells by targeting multiple tumor-associated antigens simultaneously to prevent immune escape and generate durable immunity. Patient/donor T cells are not genetically modified and therefore the cost of generating Marker’s therapies is significantly reduced.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

5

$96.60M

Marker Therapeutics has raised a total of $96.60M in funding over 2 rounds. Their latest funding was raised on Dec 13, 2022 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 13, 2022	Post-IPO Equity	$25M	1	Lincoln Park Capital Fund	—	Detail
Sep 13, 2022	Grant	$2M	1	U.S. Food and Drug Administration	—	Detail
Aug 19, 2021	Grant	$13.10M	1	Cancer Prevention and Research Institute of Texas	—	Detail
Mar 12, 2021	Post-IPO Equity	$56.50M	—	—	—	Detail
Jun 5, 1998	IPO	—	—	—	—	Detail